Pharmafile Logo
Pharmafocus logo
Advanced Search
msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016
Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …

News

NICE publishes new myeloma guidance

February 10, 2016
Medical Communications, Research and Development Farydak, Novartis, multiple myeloma

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …

News

Novartis says CDF proposals place “unreasonable” risk on pharma

February 10, 2016
Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis

Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …

News
heptares_logo

Heptares announces positive early-stage dementia trial results

February 10, 2016
Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …

News

FDA advisory committee recommends approval of Remicade biosimilar

February 10, 2016
Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion

An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

New breast cancer initiative brings together pharma and Europe’s top researchers

February 9, 2016
Medical Communications, Research and Development Pfizer, breast cancer

The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …

News
albert_bourla

Pfizer names leadership team post-Allergan merger

February 9, 2016
Manufacturing and Production, Sales and Marketing Allergan, Pfizer

Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …

Appointment
aedes_aegypti_mosquito

INTERVIEW: Tackling the Zika threat

February 9, 2016
Manufacturing and Production, Medical Communications Zika, vaccines

The Zika outbreak which started in Brazil and spread rapidly to other south American countries and beyond has taken the …

Feature
fda

FDA set to approve Remicade biosimilar

February 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima

An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …

News

NICE changes mind on Amgen’s cholesterol drug

February 8, 2016
Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha

NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …

News
uganda_health_minister_sarah_opendi_at_merck_uganda_cancer_day

Merck partners with Ugandan Health Ministry to tackle cancer awareness

February 8, 2016
Manufacturing and Production, Medical Communications Africa, Cancer, Merck

Germany’s Merck celebrated World Cancer Day by collaborating with the Uganda Ministry of Health to raise awareness about early detection …

News
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016
Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …

News
jeremy_hunt_appears_on_thye_bbcs_andrew_marr_show_february_7

UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision

February 8, 2016
Medical Communications, Sales and Marketing Jeremy Hunt, NHS

UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …

News
shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

News
Shkreli hearing

Big pharma answers tough questions at US drug pricing hearing

February 5, 2016
Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress

Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …

News

Parliamentary committee says CDF must make better use of taxpayer money

February 5, 2016
Medical Communications Cancer Drugs Fund, Public Accounts Committee

The Cancer Drugs Fund, set up to improve patients’ access to cancer drugs, has not been managed effectively, a UK …

News
Lundbeck HQ

Lundbeck gets go-ahead for US and EU licence expansions

February 4, 2016
Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine

Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …

News
Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
la76169logo

Human Longevity makes three oncology appointments

February 4, 2016
Research and Development human longevity

Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.Dr Kenneth Bloom will join …

Appointment
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026